We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · September 27, 2021

Targeting mTOR Signaling Overcomes Resistance to BRAF and MEK Inhibition in BRAF-Mutant Melanoma



Additional Info

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
Oncogene 2021 Jul 24;[EPub Ahead of Print], B Wang, W Zhang, G Zhang, L Kwong, H Lu, J Tan, N Sadek, M Xiao, J Zhang, M Labrie, S Randell, A Beroard, E Sugarman, VW Rebecca, Z Wei, Y Lu, GB Mills, J Field, J Villanueva, X Xu, M Herlyn, W Guo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading